Sanofi and Regeneron Pharmaceuticals, Inc, announce US Food and Drug Administration approval of Dupixent (dupilumab) injection, a biologic for the treatment of adults with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent is a human monoclonal antibody that inhibits overactive signaling of IL-4 and IL-3. It comes in a prefilled syringe and can be self-administered as a subcutaneous injection every other week after an initial loading dose. Dupixent MyWay will help eligible patients who are uninsured, lack coverage, or need assistance with out-of-pocket costs. For more information, visit www.dupixentHCP.com.
Samsung Bioepis Co, Ltd, announces US Food and Drug Administration approval of Renflexis (infliximab-abda) injection 100 mg, a biosimilar referencing infliximab. It is indicated in the United States for reducing signs and symptoms in patients with adult and pediatric Crohn disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and adult plaque psoriasis. Renflexis will be marketed and distributed in the United States by Merck. For more information, visit www.samsungbioepis.com.
Replenix RetinolForte Treatment Serum
Topix Pharmaceuticals, Inc, introduces Replenix Retinol Forte Treatment Serum containing all- trans -retinol, which helps increase cell turnover to reduce the appearance of fine lines and wrinkles, im- prove skin texture and tone, and promote a collagen-rich appearance. The micropolymer delivery system stabilizes the retinol to protect and shield it from oxidation while on the skin. Its time-released delivery system creates a reservoir that continuously bathes the skin and minimizes irritation. It also contains green tea polyphenols to soothe and calm the skin, caffeine to diminish the appearance of redness, and hyaluronic acid to help skin retain moisture to replenish and repair skin barrier function. For more information, visit www.topixpharm.com.
If you would like your product included in Product News, please email a press release to the Editorial Office at firstname.lastname@example.org.